Simultaneous improvements in genomic assays, novel targeted small molecule and antibody-based therapies, as well as technologies used to deliver and assess response to radiotherapy have led to renewed investigation of radiotherapy for pancreatic cancer and are presented in this special series of Annals of Pancreatic Cancer (APC).
Neoadjuvant therapy in upfront resectable pancreatic cancer: current evidence and future considerations
Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence
Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy
The series “Radiotherapy and Pancreatic Adenocarcinoma” was commissioned by the editorial office, Annals of Pancreatic Cancer without any sponsorship or funding. Richard Tuli served as the unpaid Guest Editor for the series.